| Viken Manjikian, MD | |
|
11995 Singletree Ln, Ste 500, Eden Prairie, MN 55344-5349 | |
| (952) 595-1301 | |
| (612) 294-4903 |
| Full Name | Viken Manjikian |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 34 Years |
| Location | 11995 Singletree Ln, Eden Prairie, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225094683 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 15935 (Nevada) | Secondary |
| 2085R0202X | Radiology - Diagnostic Radiology | G72109 (California) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Advanced Imaging Center, Inc. | 6406808427 | 8 |
News Archive
Exciting Australian adult stem cell company, Mesoblast Limited, today announced that it is set to begin the first human clinical trials using its specialist adult stem cells for orthopaedic and cardiovascular diseases.
Mentor Capital, Inc.'s first funding tranche to extend its investment in its proprietary Cancer Immunotherapy Index closes today. Cash investment from 1,400 existing shareholders projects to be approximately 20% oversubscribed from target. Company management reservation to fund will be correspondingly reduced to remain within the $1.2 Million seed funding limit. Already authorized follow-on public funding tranches total an additional $125 Million that will also be targeted for investment into the best of the Cancer Immunotherapy Index companies.
GlaxoSmithKline has announced that the U.S. Food and Drug Administration (FDA) has approved Twinrix [Hepatitis A Vaccine (Inactivated) and Hepatitis B (Recombinant) Vaccine], for an accelerated dosing schedule that consists of three doses given within three weeks followed by a booster dose at 12 months.
When governments use comprehensive, well-funded tobacco control programs to reduce adult smoking, they also reduce smoking among adolescents. This bonus effect is an important factor to consider as policymakers face pressure to reduce spending on anti-smoking programs.
› Verified 3 days ago
| Entity Name | Advanced Imaging Center, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467638064 PECOS PAC ID: 6406808427 Enrollment ID: O20080522000707 |
News Archive
Exciting Australian adult stem cell company, Mesoblast Limited, today announced that it is set to begin the first human clinical trials using its specialist adult stem cells for orthopaedic and cardiovascular diseases.
Mentor Capital, Inc.'s first funding tranche to extend its investment in its proprietary Cancer Immunotherapy Index closes today. Cash investment from 1,400 existing shareholders projects to be approximately 20% oversubscribed from target. Company management reservation to fund will be correspondingly reduced to remain within the $1.2 Million seed funding limit. Already authorized follow-on public funding tranches total an additional $125 Million that will also be targeted for investment into the best of the Cancer Immunotherapy Index companies.
GlaxoSmithKline has announced that the U.S. Food and Drug Administration (FDA) has approved Twinrix [Hepatitis A Vaccine (Inactivated) and Hepatitis B (Recombinant) Vaccine], for an accelerated dosing schedule that consists of three doses given within three weeks followed by a booster dose at 12 months.
When governments use comprehensive, well-funded tobacco control programs to reduce adult smoking, they also reduce smoking among adolescents. This bonus effect is an important factor to consider as policymakers face pressure to reduce spending on anti-smoking programs.
› Verified 3 days ago
| Entity Name | Stockdale Radiology Physicians Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669806402 PECOS PAC ID: 6002046422 Enrollment ID: O20140429000939 |
News Archive
Exciting Australian adult stem cell company, Mesoblast Limited, today announced that it is set to begin the first human clinical trials using its specialist adult stem cells for orthopaedic and cardiovascular diseases.
Mentor Capital, Inc.'s first funding tranche to extend its investment in its proprietary Cancer Immunotherapy Index closes today. Cash investment from 1,400 existing shareholders projects to be approximately 20% oversubscribed from target. Company management reservation to fund will be correspondingly reduced to remain within the $1.2 Million seed funding limit. Already authorized follow-on public funding tranches total an additional $125 Million that will also be targeted for investment into the best of the Cancer Immunotherapy Index companies.
GlaxoSmithKline has announced that the U.S. Food and Drug Administration (FDA) has approved Twinrix [Hepatitis A Vaccine (Inactivated) and Hepatitis B (Recombinant) Vaccine], for an accelerated dosing schedule that consists of three doses given within three weeks followed by a booster dose at 12 months.
When governments use comprehensive, well-funded tobacco control programs to reduce adult smoking, they also reduce smoking among adolescents. This bonus effect is an important factor to consider as policymakers face pressure to reduce spending on anti-smoking programs.
› Verified 3 days ago
| Entity Name | Radiology Associates Of South Florida Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699759183 PECOS PAC ID: 5799689659 Enrollment ID: O20180207002066 |
News Archive
Exciting Australian adult stem cell company, Mesoblast Limited, today announced that it is set to begin the first human clinical trials using its specialist adult stem cells for orthopaedic and cardiovascular diseases.
Mentor Capital, Inc.'s first funding tranche to extend its investment in its proprietary Cancer Immunotherapy Index closes today. Cash investment from 1,400 existing shareholders projects to be approximately 20% oversubscribed from target. Company management reservation to fund will be correspondingly reduced to remain within the $1.2 Million seed funding limit. Already authorized follow-on public funding tranches total an additional $125 Million that will also be targeted for investment into the best of the Cancer Immunotherapy Index companies.
GlaxoSmithKline has announced that the U.S. Food and Drug Administration (FDA) has approved Twinrix [Hepatitis A Vaccine (Inactivated) and Hepatitis B (Recombinant) Vaccine], for an accelerated dosing schedule that consists of three doses given within three weeks followed by a booster dose at 12 months.
When governments use comprehensive, well-funded tobacco control programs to reduce adult smoking, they also reduce smoking among adolescents. This bonus effect is an important factor to consider as policymakers face pressure to reduce spending on anti-smoking programs.
› Verified 3 days ago
| Entity Name | Mori Bean And Brooks Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093782070 PECOS PAC ID: 8820077878 Enrollment ID: O20191111002152 |
News Archive
Exciting Australian adult stem cell company, Mesoblast Limited, today announced that it is set to begin the first human clinical trials using its specialist adult stem cells for orthopaedic and cardiovascular diseases.
Mentor Capital, Inc.'s first funding tranche to extend its investment in its proprietary Cancer Immunotherapy Index closes today. Cash investment from 1,400 existing shareholders projects to be approximately 20% oversubscribed from target. Company management reservation to fund will be correspondingly reduced to remain within the $1.2 Million seed funding limit. Already authorized follow-on public funding tranches total an additional $125 Million that will also be targeted for investment into the best of the Cancer Immunotherapy Index companies.
GlaxoSmithKline has announced that the U.S. Food and Drug Administration (FDA) has approved Twinrix [Hepatitis A Vaccine (Inactivated) and Hepatitis B (Recombinant) Vaccine], for an accelerated dosing schedule that consists of three doses given within three weeks followed by a booster dose at 12 months.
When governments use comprehensive, well-funded tobacco control programs to reduce adult smoking, they also reduce smoking among adolescents. This bonus effect is an important factor to consider as policymakers face pressure to reduce spending on anti-smoking programs.
› Verified 3 days ago
| Entity Name | Integrated Imaging Consultants Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700285335 PECOS PAC ID: 2567784408 Enrollment ID: O20200715003086 |
News Archive
Exciting Australian adult stem cell company, Mesoblast Limited, today announced that it is set to begin the first human clinical trials using its specialist adult stem cells for orthopaedic and cardiovascular diseases.
Mentor Capital, Inc.'s first funding tranche to extend its investment in its proprietary Cancer Immunotherapy Index closes today. Cash investment from 1,400 existing shareholders projects to be approximately 20% oversubscribed from target. Company management reservation to fund will be correspondingly reduced to remain within the $1.2 Million seed funding limit. Already authorized follow-on public funding tranches total an additional $125 Million that will also be targeted for investment into the best of the Cancer Immunotherapy Index companies.
GlaxoSmithKline has announced that the U.S. Food and Drug Administration (FDA) has approved Twinrix [Hepatitis A Vaccine (Inactivated) and Hepatitis B (Recombinant) Vaccine], for an accelerated dosing schedule that consists of three doses given within three weeks followed by a booster dose at 12 months.
When governments use comprehensive, well-funded tobacco control programs to reduce adult smoking, they also reduce smoking among adolescents. This bonus effect is an important factor to consider as policymakers face pressure to reduce spending on anti-smoking programs.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Viken Manjikian, MD 11995 Singletree Ln, Ste 500, Eden Prairie, MN 55344-5349 Ph: (952) 595-1301 | Viken Manjikian, MD 11995 Singletree Ln, Ste 500, Eden Prairie, MN 55344-5349 Ph: (952) 595-1301 |
News Archive
Exciting Australian adult stem cell company, Mesoblast Limited, today announced that it is set to begin the first human clinical trials using its specialist adult stem cells for orthopaedic and cardiovascular diseases.
Mentor Capital, Inc.'s first funding tranche to extend its investment in its proprietary Cancer Immunotherapy Index closes today. Cash investment from 1,400 existing shareholders projects to be approximately 20% oversubscribed from target. Company management reservation to fund will be correspondingly reduced to remain within the $1.2 Million seed funding limit. Already authorized follow-on public funding tranches total an additional $125 Million that will also be targeted for investment into the best of the Cancer Immunotherapy Index companies.
GlaxoSmithKline has announced that the U.S. Food and Drug Administration (FDA) has approved Twinrix [Hepatitis A Vaccine (Inactivated) and Hepatitis B (Recombinant) Vaccine], for an accelerated dosing schedule that consists of three doses given within three weeks followed by a booster dose at 12 months.
When governments use comprehensive, well-funded tobacco control programs to reduce adult smoking, they also reduce smoking among adolescents. This bonus effect is an important factor to consider as policymakers face pressure to reduce spending on anti-smoking programs.
› Verified 3 days ago
Norna L. Karp, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 11995 Singletree Ln Ste 500, Eden Prairie, MN 55344 Phone: 952-595-1301 Fax: 612-294-4903 | |
Paul D Guisler, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 11995 Singletree Ln Ste 500, Eden Prairie, MN 55344 Phone: 952-595-1301 Fax: 612-294-4903 | |
Rati N Patel, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 11995 Singletree Ln Ste 500, Eden Prairie, MN 55344 Phone: 952-595-1301 Fax: 612-294-4903 | |
Jacob Gebrael, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 11995 Singletree Ln Ste 500, Eden Prairie, MN 55344 Phone: 952-595-1301 Fax: 612-294-4903 | |
Susanne S. Kim, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 11995 Singletree Ln Ste 500, Eden Prairie, MN 55344 Phone: 952-595-1301 Fax: 612-294-4903 | |
Gwendolyn Durgin, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 11995 Singletree Ln Ste 500, Eden Prairie, MN 55344 Phone: 952-595-1301 Fax: 612-294-4903 | |
Stephen George Fox, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 11995 Singletree Ln Ste 500, Eden Prairie, MN 55344 Phone: 952-595-1301 Fax: 612-294-4903 |